DistantNews
Support us
🇹🇼 Taiwan /Economy & Trade

PharmaEngine Stock Resilient Despite Losing Second Arbitration Case

From Liberty Times · () Chinese

Translated from Chinese, summarized and contextualized by DistantNews.

At a glance

News Named sources Outcome reported
  • PharmaEngine Inc. lost a second arbitration case against international pharmaceutical company AOP concerning royalty payments and product rights.
  • Despite the loss, PharmaEngine's stock price showed resilience, opening lower but then rising due to market perception of minimal financial impact.
  • The company stated the arbitration outcome would not significantly affect its financial or business operations, citing offsetting claims and plans to challenge the ruling.

PharmaEngine Inc. (6446) has suffered another setback in its ongoing arbitration dispute with international pharmaceutical firm AOP, receiving a partial arbitral award against it in the second phase of the case. The International Court of Arbitration of the International Chamber of Commerce delivered the ruling on August 8.

Despite the negative arbitration outcome, PharmaEngine's stock demonstrated surprising resilience. The shares opened lower on the news, but quickly recovered, showing a significant intraday swing. Market analysts suggest this resilience stems from the company's assertion that the financial implications are manageable. PharmaEngine stated that while it is required to pay AOP nearly 100 million Euros (approximately NT$3.6 billion) in royalties and payments, AOP also owes PharmaEngine a similar amount in unpaid royalties and product fees since the second half of 2023.

Although we need to pay AOP three amounts totaling nearly 100 million Euros (approximately NT$3.6 billion), AOP's unpaid royalties and product fees owed to PharmaEngine have also totaled nearly 100 million Euros since the second half of 2023. Therefore, the offsetting of these amounts means the arbitral award has no significant impact on the company's financial and business operations.

— PharmaEngine Inc.Explaining the financial impact of the arbitration ruling.

PharmaEngine's management indicated that these offsetting claims significantly mitigate the financial impact of the arbitration award. The company further announced its intention to explore options for challenging the arbitral award. This strategic move appears to have reassured investors, preventing a steeper decline in the stock price.

As of the morning trading session on August 10, PharmaEngine's stock was trading at NT$1,290, up NT$50, or 4%, on a trading volume of nearly 1,500 shares. The company's ability to navigate these legal and financial challenges while maintaining market confidence will be closely watched.

The company will also explore plans to challenge the arbitral award.

— PharmaEngine Inc.Stating the company's intention to contest the arbitration decision.
DistantNews Editorial

Originally published by Liberty Times in Chinese. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog